{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T22:41:09Z","timestamp":1771022469652,"version":"3.50.1"},"reference-count":31,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T00:00:00Z","timestamp":1703376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Karl Landsteiner University of Health Sciences"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Evoked from asbestos-induced inflammation, pleural mesothelioma represents a fatal diagnosis. Therapy ranges from nihilism to aggressive multimodality regimens. However, it is still unclear who ultimately benefits from which treatment. We aimed to re-challenge inflammatory-related biomarkers\u2019 prognostic value in times of modern immune-oncology and lung-sparing surgery. The biomarkers (leukocytes, hemoglobin, platelets, neutrophils, lymphocytes, monocytes, neutrophil\u2013lymphocyte ratio (NLR), lymphocyte\u2013monocyte ratio (LMR), platelet\u2013lymphocyte ratio (PLR), C-reactive protein (CRP)) and clinical characteristics (age, sex, histology, therapy) of 98 PM patients were correlated to overall survival (OS). The median OS was 19.4 months. Significant OS advantages (Log-Rank) were observed in multimodal treatment vs. others (26.1 vs. 7.2 months, p &lt; 0.001), surgery (pleurectomy\/decortication) vs. no surgery (25.5 vs. 3.8 months, p &lt; 0.001), a high hemoglobin level (cut-off 12 g\/dL, 15 vs. 24.2 months, p = 0.021), a low platelet count (cut-off 280 G\/L, 26.1 vs. 11.7 months, p &lt; 0.001), and a low PLR (cut-off 194.5, 25.5 vs. 12.3 months, p = 0.023). Histology (epithelioid vs. non-epithelioid, p = 0.002), surgery (p = 0.004), CRP (cut-off 1 mg\/dL, p = 0.039), and platelets (p = 0.025) were identified as independent prognostic variables for this cohort in multivariate analysis (Cox regression, covariates: age, sex, histology, stage, CRP, platelets). Our data verified the previously shown prognostic role of systemic inflammatory parameters in patients treated with lung-sparing surgery within multimodality therapy.<\/jats:p>","DOI":"10.3390\/cancers16010093","type":"journal-article","created":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T20:49:27Z","timestamp":1703450967000},"page":"93","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Validation of Inflammatory Prognostic Biomarkers in Pleural Mesothelioma"],"prefix":"10.3390","volume":"16","author":[{"given":"Stephanie","family":"Iser","sequence":"first","affiliation":[{"name":"Karl Landsteiner University of Health Sciences, Dr. Karl-Dorrek-Stra\u00dfe 30, 3500 Krems, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Hintermair","sequence":"additional","affiliation":[{"name":"Department of General and Thoracic Surgery, University Hospital Krems, Mitterweg 10, 3500 Krems, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Varga","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital Krems, 3500 Krems, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"\u00c7elik","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, School of Medicine, Gazi University, Besevler, 06500 Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammet","family":"Sayan","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, School of Medicine, Gazi University, Besevler, 06500 Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5048-6115","authenticated-orcid":false,"given":"Aykut","family":"Kanko\u00e7","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, School of Medicine, Gazi University, Besevler, 06500 Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nalan","family":"Aky\u00fcrek","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, Gazi University, Besevler, 06500 Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bet\u00fcl","family":"\u00d6\u011f\u00fct","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, Gazi University, Besevler, 06500 Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6267-0099","authenticated-orcid":false,"given":"Pietro","family":"Bertoglio","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, IRCCS Azienda Ospedaliero Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Capozzi","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, IRCCS Azienda Ospedaliero Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piergiorgio","family":"Solli","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, IRCCS Azienda Ospedaliero Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4023-0578","authenticated-orcid":false,"given":"Luigi","family":"Ventura","sequence":"additional","affiliation":[{"name":"Barts Thorax Centre, St Bartholomew\u2019s Hospital, Barts Health NHS Trust, London EC1A 7BS, UK"},{"name":"Department of Thoracic Surgery, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield S10 2JF, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Waller","sequence":"additional","affiliation":[{"name":"Barts Thorax Centre, St Bartholomew\u2019s Hospital, Barts Health NHS Trust, London EC1A 7BS, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Weber","sequence":"additional","affiliation":[{"name":"Division of Biostatistics and Data Science, Department of General Health Studies, Karl Landsteiner University of Health Sciences, Dr. Karl-Dorrek-Stra\u00dfe 30, 3500 Krems, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Stubenberger","sequence":"additional","affiliation":[{"name":"Department of General and Thoracic Surgery, University Hospital Krems, Mitterweg 10, 3500 Krems, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6563-5643","authenticated-orcid":false,"given":"Bahil","family":"Ghanim","sequence":"additional","affiliation":[{"name":"Karl Landsteiner University of Health Sciences, Dr. Karl-Dorrek-Stra\u00dfe 30, 3500 Krems, Austria"},{"name":"Department of General and Thoracic Surgery, University Hospital Krems, Mitterweg 10, 3500 Krems, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s13665-013-0045-1","article-title":"Prognostic factors for malignant pleural mesothelioma","volume":"2","author":"Brims","year":"2013","journal-title":"Curr. Respir. Care Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1200\/JCO.2008.19.8523","article-title":"Malignant pleural mesothelioma","volume":"27","author":"Tsao","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s13014-015-0575-5","article-title":"Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy, and intensity-modulated radiotherapy","volume":"10","author":"Thieke","year":"2015","journal-title":"Radiat. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.clon.2022.08.029","article-title":"What\u2019s Current and What\u2019s New in Mesothelioma?","volume":"34","author":"Leal","year":"2022","journal-title":"Clin. Oncol."},{"key":"ref_5","first-page":"e20210129","article-title":"Malignant pleural mesothelioma: An update","volume":"47","author":"Hajj","year":"2021","journal-title":"J. Bras. Pneumol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Vogl, M., Rosenmayr, A., Bohanes, T., Scheed, A., Brndiar, M., Stubenberger, E., and Ghanim, B. (2021). Biomarkers for Malignant Pleural Mesothelioma-A Novel View on Inflammation. Cancers, 13.","DOI":"10.3390\/cancers13040658"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.jtcvs.2012.09.023","article-title":"Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and\/or pleurodesis","volume":"145","author":"Baud","year":"2013","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_9","first-page":"445","article-title":"Prognostic Impact of Inflammation-related Biomarkers on Overall Survival of Patients with Inoperable Malignant Pleural Mesothelioma","volume":"32","author":"Takehiro","year":"2018","journal-title":"In Vivo"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"21861","DOI":"10.18632\/oncotarget.25076","article-title":"Prognostic and diagnostic impact of fibrinogen, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio on thymic epithelial tumors outcome","volume":"9","author":"Janik","year":"2018","journal-title":"Oncotarget"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.lungcan.2017.07.024","article-title":"Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab","volume":"11","author":"Diem","year":"2017","journal-title":"Lung Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/bjc.2013.815","article-title":"Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma","volume":"110","author":"Ghanim","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/SLA.0b013e3182602af4","article-title":"Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: A retrospective multicenter analysis","volume":"256","author":"Ghanim","year":"2012","journal-title":"Ann. Surg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.1989.7.8.1157","article-title":"Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: A retrospective study of 332 patients","volume":"7","author":"Ruffie","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/00001622-199104000-00014","article-title":"Pleural mesothelioma","volume":"3","author":"Ruffie","year":"1991","journal-title":"Curr. Opin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jtho.2015.10.003","article-title":"Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma","volume":"11","author":"Krug","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1080\/09537104.2016.1246712","article-title":"Pretreatment thrombocytosis as a significant prognostic factor in malignant mesothelioma: A meta-analysis","volume":"28","author":"Zhuo","year":"2017","journal-title":"Platelets"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.1038\/s41598-020-62813-2","article-title":"Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: The impact of C-reactive protein and immune-checkpoint inhibition","volume":"10","author":"Ghanim","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_19","unstructured":"Rokkam, V.R., Killeen, R.B., and Kotagiri, R. (2023). Secondary Thrombocytosis, StatPearls Publishing."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ccell.2018.03.002","article-title":"The Platelet Lifeline to Cancer: Challenges and Opportunities","volume":"33","author":"Haemmerle","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"9323","DOI":"10.1007\/s13277-015-4774-3","article-title":"Combination of platelet count and mean platelet volume (COP-MPV) predicts postoperative prognosis in both resectable early and advanced stage esophageal squamous cell cancer patients","volume":"37","author":"Zhang","year":"2016","journal-title":"Tumor Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"15632","DOI":"10.18632\/oncotarget.14921","article-title":"Prognostic value of combination of preoperative platelet count and mean platelet volume in patients with resectable non-small cell lung cancer","volume":"8","author":"Gao","year":"2017","journal-title":"Oncotarget"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/03936155221118098","article-title":"Platelet-to-lymphocyte ratio associated with the clinicopathological features and prognostic value of breast cancer: A meta-analysis","volume":"37","author":"Gong","year":"2022","journal-title":"Int. J. Biol. Markers"},{"key":"ref_24","first-page":"651","article-title":"Are neutrophil\/lymphocyte ratio and platelet\/lymphocyte ratio reliable parameters as prognostic indicators in malignant mesothelioma?","volume":"12","author":"Sokucu","year":"2016","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1099685","DOI":"10.3389\/fmed.2023.1099685","article-title":"Prognostic significance of inflammation-related and electrolyte laboratory variables in patients with malignant pleural mesothelioma","volume":"10","author":"Zhang","year":"2023","journal-title":"Front. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.7314\/APJCP.2014.15.5.2061","article-title":"Relationship between prognosis and neutrophil: Lymphocyte and platelet:lymphocyte ratios in patients with malignant pleural mesotheliomas","volume":"15","author":"Cihan","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41379-021-00895-7","article-title":"Pleural mesothelioma classification-update and challenges","volume":"35","author":"Dacic","year":"2022","journal-title":"Mod. Pathol."},{"key":"ref_28","first-page":"471","article-title":"C-reactive protein and malignancy: Clinico-pathological association and therapeutic implication","volume":"32","author":"Wang","year":"2009","journal-title":"Chang. Gung Med. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.jtho.2018.08.001","article-title":"Surgery in Malignant Pleural Mesothelioma","volume":"13","author":"Bueno","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1586\/17476348.2016.1171147","article-title":"The role of thoracic surgery in the management of mesothelioma: An expert opinion on the limited evidence","volume":"10","author":"Bertoglio","year":"2016","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_31","unstructured":"Gebhart, F. (2023, October 20). MARS2: Decortication Plus Chemotherapy Associated with Worse Outcomes for Resectable Mesothelioma. Available online: https:\/\/www.ilcn.org\/mars2-decortication-plus-chemotherapy-associated-with-worse-outcomes-for-resectable-mesothelioma\/."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/1\/93\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:41:13Z","timestamp":1760132473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/1\/93"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,24]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["cancers16010093"],"URL":"https:\/\/doi.org\/10.3390\/cancers16010093","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,24]]}}}